Background: Trabectedin (T) is an anti-tumor agent used in the treatment of advanced soft-tissue sarcomas (STS). It interferes with DNA replication, causing double strand breaks and apoptosis, and may deplete tumor-associated macrophages in the tumor microenvironment. T was recently USFDA- approved for advanced liposarcoma and leiomyosarcoma. We report the largest known single-center experience in advanced soft-tissue sarcoma treated with T. Methods: This retrospective study includes 442 advanced STS patients treated with T from 2005-2015 as part of various clinical trials. Baseline characteristics and treatment outcomes by histologic subtypes were assessed by RECIST 1.1 criteria. Progression-free survival (PFS) in months was determined in evaluable patients who completed at least 2 cycles of T, and had a follow-up CT scan or MRI. Results: The table shows the demographics and PFS of various subtypes of sarcoma. The median PFS for advanced leiomyosarcoma and liposarcoma (3.7 and 4.3 months respectively) was similar to that reported by Demetri et al., 2014, in a Phase 3 study using trabectedin vs dacarbazine (4.2 vs 1.5 months respectively) (1). Notably, durable disease control was also noted in synovial cell sarcoma and chondrosarcoma (median PFS 6.8 and 4.5 months respectively). Adverse events profile of T was similar to previous studies. Conclusions: Taken together, the data suggests that T may also prolong progression-free survival in patients with advanced synovial cell sarcoma and chondrosarcoma, warranting further studies. Clinical trial information: Multiple clinical trials.